J&J revenue sees first decline in 76 years

While overall earnings were ahead of what analysts predicted for drugmaker Johnson & Johnson, it is clear that generic competition has hurt the company's sales. The company earned $2.6 billion (94 cents per share) in the fourth quarter, a little more than it did in the fourth quarter of 2007, when it earned $2.5 billion (88 cents per share).

While its consumer products division showed a 1.2 percent increase in sales globally, its medical device unit sales were down by 1.9 percent. Cordis, a J&J unit that makes stents, saw sales drop to $722 million, or to 16.8 percent. However, its prescription medications took the greatest hit. Sales of Razadyne, its medication for Alzheimer disease dropped by 77.6 percent to $11 million, and Risperdal, dropped 84 percent since the fourth quarter of 2007.

Overall, the company reported a 4.9 percent decline in revenue to $15.8 billion, the company's first revenue decline in 76 years.

J&J chairperson Bill Weldon said that J&J is confident it is positioned well for growth, and that the company has made significant progress in its research pipeline.

- read the story in the Wall Street Journal
- find out more at CNN Money 
- see what Forbes has to say

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.